Compare IDEXX Laboratories, Inc. (IDXX) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs New York Times Co — how do they compare? IDEXX Laboratories, Inc. trades at $551.53 (market cap $44.48B), while New York Times Co trades at $74.78 (market cap $12.29B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.6× New York Times Co's market cap, and New York Times Co pays a 1.21% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | NYT | |
|---|---|---|
Market Cap | $44.48B | $12.29B |
Sector | Health | Media |
52-Week High | $766.68 | $85.86 |
52-Week Low | $520.87 | $51.43 |
Enterprise Value | $45.38B | $11.68B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
The New York Times Company (NYSE: NYT) trades at $75.44, down 0.65% today, with a bullish technical signal and strong fundamentals. Revenue grew to $2.82B in 2025, with net income reaching $344M and profit margins expanding to 12.17%. Recent quarters show consistent earnings beats, and the company announced a $0.23 dividend payable July 23, 2026. Positive cash flow from operations of $584M supports financial health, while analyst consensus price target is $78.00.
Outlook remains positive with steady revenue growth and profitability, though high valuation multiples (P/E 32.59) pose risks. Key catalysts include Q2 2026 earnings on August 5, 2026, and ongoing digital subscription growth. Risks involve regulatory pressures from recent subpoenas to journalists and competitive media landscape. Institutional sentiment is mixed with 29% buy ratings, suggesting cautious optimism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
